{"id":3879,"date":"2017-11-22T08:19:04","date_gmt":"2017-11-22T08:19:04","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/"},"modified":"2017-11-22T08:19:04","modified_gmt":"2017-11-22T08:19:04","slug":"nanexas-foretradesemission-pa-229-msek-overtecknades","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/","title":{"rendered":"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades"},"content":{"rendered":"
Den 20 november 2017 avslutades teckningstiden i Nanexa AB:s f\u00f6retr\u00e4desemission.<\/strong><\/div>\n

F\u00f6retr\u00e4desemissionen tecknades till ca 25,1 MSEK, motsvarande en teckning om ca 110 %. Genom f\u00f6retr\u00e4desemissionen tillf\u00f6rs bolaget 22,9 MSEK f\u00f6re emissionskostnader. Emissionskostnaderna f\u00f6rv\u00e4ntas uppg\u00e5 till ca 4,6 MSEK inklusive kontant ers\u00e4ttning f\u00f6r garanti\u00e5taganden.<\/p>\n

VD David Westberg kommenterar resultatet i emissionen<\/p>\n

Vi \u00e4r oerh\u00f6rt glada och tacksamma f\u00f6r det f\u00f6rtroendet f\u00f6r bolaget som befintliga och nya aktie\u00e4gare visat i denna emission. Med detta kapitaltillskott kan vi genomf\u00f6ra aktiviteter som m\u00f6jligg\u00f6r och befr\u00e4mjar samarbeten och avtal f\u00f6r bolagets drug delivery-plattform PharmaShell\u00ae. Dessa aktiviteter kommer att p\u00e5b\u00f6rjas redan i b\u00f6rjan av 2018. Aktiviteterna kommer att inkludera vidare utveckling av PharmaShell\u00aef\u00f6r att p\u00e5visa dess unika egenskaper b\u00e5de i laboratorief\u00f6rs\u00f6k och i flera djurstudier. Dessutom kommer vi, som tidigare kommunicerats, starta och driva ett eget produktprojekt baserat p\u00e5 PharmaShell\u00aef\u00f6r att p\u00e5 s\u00e5 vis utvidga aff\u00e4rsm\u00f6jligheterna. Vi kommer ocks\u00e5 att \u00f6ka v\u00e5r n\u00e4rvaro p\u00e5 framst\u00e5ende kommersiella och vetenskapliga konferenser b\u00e5de i Europa och i USA, d\u00e4r resultaten fr\u00e5n utvecklingsaktiviteterna kommer vara kritiska i kommunikationen med potentiella partners.<\/p>\n

Antal aktier och aktiekapital<\/p>\n

N\u00e4r f\u00f6retr\u00e4desemissionen registreras hos Bolagsverket kommer antalet aktier i Nanexa uppg\u00e5 till 11\u00a0437 581 stycken och aktiekapitalet kommer uppg\u00e5 till 1\u00a0480\u00a0267,50 SEK.<\/p>\n

Handel med BTU<\/p>\n

Handel med betalda tecknade units, BTU, kommer att ske p\u00e5 AktieTorget fram till dess att Bolagsverket har registrerat f\u00f6retr\u00e4desemissionen. Registreringen ber\u00e4knas ske under december 2017.<\/p>\n

Tilldelning i f\u00f6retr\u00e4desemissionen<\/p>\n

Totalt inkom anm\u00e4lningar motsvarande ca 25,1 MSEK inklusive tecknings\u00e5taganden. 2 903 579 units tilldelas tecknare med st\u00f6d av f\u00f6retr\u00e4desr\u00e4tt vilket motsvarar cirka 76% procent av emissionsvolymen. De som tilldelas units utan st\u00f6d av f\u00f6retr\u00e4desr\u00e4tt kommer att erh\u00e5lla avr\u00e4kningsnotor, vilka \u00e4r ber\u00e4knade att skickas ut fr\u00e5n och med 23 november 2017.<\/p>\n

R\u00e5dgivare<\/p>\n

G\u00f6teborg Corporate Finance AB \u00e4r finansiell r\u00e5dgivare till Nanexa i samband med f\u00f6retr\u00e4desemissionen och Mangold Fondkommission \u00e4r emissionsinstitut.<\/p>\n

Denna information \u00e4r s\u00e5dan information som Nanexa AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 22 november 2017.<\/p>\n

F\u00f6r mer information kontakta:<\/p>\n

David Westberg – VD, Nanexa AB (publ)\u00a0<\/p>\n

Telefon: 0709 – 42 83 03<\/p>\n

E-post:\u00a0david.westberg@nanexa.se\u00a0<\/p>\n

www.nanexa.com<\/p>\n

Om Nanexa AB (publ)<\/p>\n

Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Den 20 november 2017 avslutades teckningstiden i Nanexa AB:s f\u00f6retr\u00e4desemission.<\/p>\n","protected":false},"template":"","class_list":["post-3879","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ca-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Den 20 november 2017 avslutades teckningstiden i Nanexa AB:s f\u00f6retr\u00e4desemission.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-foretradesemission-pa-229-msek-overtecknades\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-foretradesemission-pa-229-msek-overtecknades\\\/\",\"name\":\"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2017-11-22T08:19:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-foretradesemission-pa-229-msek-overtecknades\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-foretradesemission-pa-229-msek-overtecknades\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-foretradesemission-pa-229-msek-overtecknades\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades - Nanexa AB","og_description":"Den 20 november 2017 avslutades teckningstiden i Nanexa AB:s f\u00f6retr\u00e4desemission.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/","name":"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2017-11-22T08:19:04+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-foretradesemission-pa-229-msek-overtecknades\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexas f\u00f6retr\u00e4desemission p\u00e5 22,9 MSEK \u00f6vertecknades"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}